138 results on '"Benedict, Agnes"'
Search Results
2. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
3. A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective
4. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
5. A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
6. P857: COMPARISON OF MULTIPLE MYELOMA TREATMENT PATTERNS IN 2022 ACROSS UNITED STATES, SOUTH AMERICA, EUROPE AND ASIA
7. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
8. Simulation and Matching-Based Approaches for Indirect Comparison of Treatments
9. Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges
10. Overview of Parametric Survival Analysis for Health-Economic Applications
11. 219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients
12. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
13. Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer - a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
14. TOTAL COST IN THE 1ST YEAR FOLLOWING DIAGNOSIS OF PROSTATE CANCER: ESTIMATES FROM US SEER-MEDICARE DATA: 168
15. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
16. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
17. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost–effectiveness analysis
18. Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.
19. Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)
20. Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
21. Indirect Comparison to Assess the Relative Efficacy of Carfilzomib + Lenalidomide + Dexamethasone Versus Bortezomib + Thalidomide + Dexamethasone: A Matching Adjusted Indirect Comparison
22. Indirect Comparisons to Assess the Relative Efficacy of Carfilzomib + Lenalidomide + Dexamethasone Versus Panobinostat + Bortezomib + Dexamethasone and Bortezomib + Dexamethasone: A Matching Adjusted Indirect Comparison
23. Acknowledgement.
24. Overall survival information and population correspondence for FDA cancer accelerated approval indications between 2006 and 2021.
25. Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States
26. Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
27. Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
28. Modelling survival in hepatocellular carcinoma
29. Retrospective claims analysis of palliative care costs and survival in a U.S. metastatic renal cell (mRCC) population.
30. Potential economic impact of increasing low dose aspirin usage on CVD in the US
31. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia
32. Violence in the Classroom.
33. SUNBEAMS.
34. Farm Children.
35. Children at the Cross Roads
36. Play Centers for School Children: A Guide to Their Establishment and Operation.
37. Your Best Friends Are Your Children
38. Book Review: Social Work Book-of-the-Month: Parents and Children Go to School
39. The Happy Home: A Guide to Family Living
40. Children at the Crossroads
41. The Elements of Education.
42. Security and Stimulation.
43. Realities of Implementing Community-Based Learning during Lockdown: Lessons from a Troubled Journey.
44. A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer.
45. S: Pages 394-581.
46. Referee Acknowledgement for 2009.
47. Peabody bimonthly booknotes.
48. Peabody bimonthly booknotes.
49. CHAPTER VI: Reshaping Educational Policy.
50. BIBLIOGRAPHY.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.